CHROMADEX CORP (CDXC) Stock Price, Forecast & Analysis
NASDAQ:CDXC • US1710774076
CDXC Key Statistics, Chart & Performance
The current stock price of CDXC is 7.87 USD. In the past month the price increased by 33.16%. In the past year, price increased by 121.07%.
CDXC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDXC. When comparing the yearly performance of all stocks, CDXC is one of the better performing stocks in the market, outperforming 98.21% of all stocks.
CDXC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CDXC. CDXC has an excellent financial health rating, but there are some minor concerns on its profitability.
CDXC Financial Highlights
Over the last trailing twelve months CDXC reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 242.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.58% | ||
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| Debt/Equity | 0 |
CDXC Forecast & Estimates
9 analysts have analysed CDXC and the average price target is 9.21 USD. This implies a price increase of 16.97% is expected in the next year compared to the current price of 7.87.
For the next year, analysts expect an EPS growth of 19% and a revenue growth 20.72% for CDXC
CDXC Ownership
CDXC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.34 | 189.666B | ||
| DHR | DANAHER CORP | 25.03 | 150.273B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 133.24 | 44.271B | ||
| A | AGILENT TECHNOLOGIES INC | 20.78 | 35.584B | ||
| IQV | IQVIA HOLDINGS INC | 12.76 | 28.313B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.44 | 27.668B | ||
| WAT | WATERS CORP | 22.35 | 19.25B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.91 | 18.02B | ||
| ILMN | ILLUMINA INC | 22.56 | 17.849B | ||
| MEDP | MEDPACE HOLDINGS INC | 25.46 | 12.058B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDXC
Company Profile
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The firm is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Company Info
CHROMADEX CORP
10900 Wilshire Blvd, Suite 600
Los Angeles CALIFORNIA 90024 US
CEO: Robert Fried
Employees: 106
Phone: 13103886706
CHROMADEX CORP / CDXC FAQ
What does CDXC do?
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The firm is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Can you provide the latest stock price for CHROMADEX CORP?
The current stock price of CDXC is 7.87 USD. The price decreased by -0.88% in the last trading session.
What is the dividend status of CHROMADEX CORP?
CDXC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDXC stock?
CDXC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists CDXC stock?
CDXC stock is listed on the Nasdaq exchange.
How is the market expecting CDXC stock to perform?
9 analysts have analysed CDXC and the average price target is 9.21 USD. This implies a price increase of 16.97% is expected in the next year compared to the current price of 7.87.
Would investing in CHROMADEX CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CDXC.